利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.016 秒)

    TRPV1 + SENSORY NEURONS CONTROL OF BETA-CELL STRESS AND ISLET INFLAMMATION IN DIABETES
    2.
    发明申请
    TRPV1 + SENSORY NEURONS CONTROL OF BETA-CELL STRESS AND ISLET INFLAMMATION IN DIABETES 审中-公开
    TRPV1 +感觉神经元控制糖尿病患者的细胞应力和血小板渗透

    公开(公告)号：US20090221511A1

    公开(公告)日：2009-09-03

    申请号：US12394261

    申请日：2009-02-27

    申请人： Hans-Michael DOSCH ,  Lan Tang ,  Yin Chan ,  Michael Salter

    发明人： Hans-Michael DOSCH ,  Lan Tang ,  Yin Chan ,  Michael Salter

    IPC分类号： A61K38/08 ,  A61K31/165 ,  A61P3/10

    CPC分类号： A61K38/046 ,  Y10S514/866

    摘要： A process is disclosed for controlling inflammatory tissue access through release of neuropeptides, such as substance P (sP), to insulin-responsive sensory neurons, whereby simultaneous control of insulin sensitivity/resistance is manifested. In models of Type 1 and Type 2 diabetes, sensory afferents, in particular TRPV1, have fundamental roles in insulin/glucose homeostasis, islet physiology and autoimmune tissue inflammation. By manipulation of the TRPV1 neuro-β-cell circuit or enhancement of pancreatic sP levels, normalization of insulin resistance, clearance of inflammation and prevention of both Type 1 and Type 2 diabetes is realized.

    摘要翻译： 公开了一种通过将神经肽（例如物质P（sP））释放到胰岛素反应性感觉神经元来控制炎症组织进入的方法，由此表现出胰岛素敏感性/抗性的同时控制。 在1型和2型糖尿病模型中，感觉传入特别是TRPV1在胰岛素/葡萄糖体内平衡，胰岛生理和自身免疫组织炎症中具有重要作用。 通过操纵TRPV1神经 - β细胞电路或增强胰腺sP水平，实现胰岛素抵抗的正常化，炎症清除和预防1型和2型糖尿病。

    Rapid release mechanism with damping control
    3.
    发明授权
    Rapid release mechanism with damping control 失效
    具有阻尼控制的快速释放机构

    公开(公告)号：US5860443A

    公开(公告)日：1999-01-19

    申请号：US808724

    申请日：1997-02-28

    申请人： John Soemer ,  Peter Materna ,  Michael Dosch ,  Richard Moakes ,  Geoffrey Lawrence Mahon

    发明人： John Soemer ,  Peter Materna ,  Michael Dosch ,  Richard Moakes ,  Geoffrey Lawrence Mahon

    IPC分类号： B60R21/26 ,  F16K17/04 ,  F16K17/40 ,  F16K31/00 ,  F16K31/128 ,  F17C13/04

    CPC分类号： F16K13/04 ,  Y10T137/1774

    摘要： A release mechanism for releasing pressurized fluid from an associated pressure vessel has sealing means for use in sealing an opening in the associated pressure vessel, supporting means for supporting the sealing means, first opening means for selectively opening the sealing means by removing the supporting means and, damping control means for damping the supporting means and also regulating the release of the high pressure fluid. To release pressurized fluid from the pressure vessel, the supporting means is removed out of supporting relationship with a sealing means. Next the supporting means is moved along its axis without damping, then with damping and, finally, with relatively light damping.

    摘要翻译： 用于从相关压力容器释放加压流体的释放机构具有用于密封相关压力容器中的开口的密封装置，用于支撑密封装置的支撑装置，用于通过移除支撑装置来选择性地打开密封装置的第一打开装置， 阻尼控制装置，用于阻尼支撑装置并调节高压流体的释放。 为了从压力容器释放加压流体，支撑装置与密封装置脱离支撑关系。 接下来，支撑装置沿其轴线移动而没有阻尼，然后是阻尼，最后以相对较轻的阻尼运动。

    METHOD FOR REVERSING RECENT-ONSET TYPE 1 DIABETES (T1D) BY ADMINISTERING SUBSTANCE P (sP)
    4.
    发明申请
    METHOD FOR REVERSING RECENT-ONSET TYPE 1 DIABETES (T1D) BY ADMINISTERING SUBSTANCE P (sP) 审中-公开
    通过管理物质P（sP）反转最近一型糖尿病（T1D）的方法

    公开(公告)号：US20150099697A1

    公开(公告)日：2015-04-09

    申请号：US14244990

    申请日：2014-04-04

    申请人： Hans-Michael DOSCH

    发明人： Hans-Michael DOSCH

    IPC分类号： A61K38/08 ,  C12Q1/68 ,  A61K9/00

    CPC分类号： C12Q1/6883 ,  A61K9/0019 ,  A61K38/046 ,  A61K38/08 ,  C12Q2600/106 ,  C12Q2600/156

    摘要： Described herein is a treatment comprising the following step: (a) injecting a therapeutically effective amount of a pharmaceutical composition into the celiac artery of an individual, wherein the pharmaceutical composition reverses recent onset Type 1 Diabetes (T1D). Also described is a method for identifying an individual who will be responsive to this treatment. In addition there is described a device containing the pharmaceutical composition for injecting the pharmaceutical composition into the celiac artery.

    摘要翻译： 本文描述的治疗包括以下步骤：（a）将治疗有效量的药物组合物注射到个体的腹腔动脉中，其中药物组合物逆转最近发病的1型糖尿病（T1D）。 还描述了一种用于识别对这种治疗有反应的个体的方法。 此外，还描述了含有用于将药物组合物注入腹腔动脉的药物组合物的装置。

    LYMPHOCYTE CONTROL OF OBESITY AND INSULIN RESISTANCE
    5.
    发明申请
    LYMPHOCYTE CONTROL OF OBESITY AND INSULIN RESISTANCE 审中-公开
    肥胖和胰岛素抵抗的淋巴管控制

    公开(公告)号：US20110091447A1

    公开(公告)日：2011-04-21

    申请号：US12922227

    申请日：2009-03-13

    申请人： Hans-Michael Dosch ,  Yin Chan ,  Shawn Winer ,  Geoffrey Palster

    发明人： Hans-Michael Dosch ,  Yin Chan ,  Shawn Winer ,  Geoffrey Palster

    IPC分类号： A61K39/395 ,  A61P3/00 ,  A61P3/10

    CPC分类号： A61K38/2093 ,  C07K16/244 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/76 ,  A61K2300/00

    摘要： Methods for the treatment, inhibition, prevention, etc. of metabolic syndrome (MetSyn) and/or Type-2 diabetes (T2D) using a T cell activating antibody that stimulates activation and immunomodulation of T-cells to affect the immune environment of adipose tissue and improve insulin sensitivity. Also methods for the treatment, inhibition, prevention, amelioration, reversal, etc., of metabolic syndrome (MetSyn) and/or Type-2 diabetes (T2D) using leukemia inhibitory factor (LIF), or a functional portion thereof. Compositions administered to individuals having or at risk of developing MetSyn and/or T2D may include pharmaceutical compositions. Methods may also provide tolerogenic vaccines based on the administration of identified auto-antigens from individuals having or at risk of developing MetSyn and/or T2D.

    摘要翻译： 使用刺激T细胞的活化和免疫调节以影响脂肪组织的免疫环境的T细胞活化抗体来治疗，抑制，预防代谢综合征（MetSyn）和/或2型糖尿病（T2D）的方法 并提高胰岛素敏感性。 还有使用白血病抑制因子（LIF）或其功能部分的代谢综合征（MetSyn）和/或2型糖尿病（T2D）的治疗，抑制，预防，改善，逆转等的方法。 对具有或有开发MetSyn和/或T2D风险的个体施用的组合物可包括药物组合物。 方法还可以提供基于从具有或有开发MetSyn和/或T2D风险的个体给予鉴定的自身抗原的耐受性疫苗。

    Method for reversing recent-onset type 1 diabetes (T1D) by administering substance P (sP)
    8.
    发明授权
    Method for reversing recent-onset type 1 diabetes (T1D) by administering substance P (sP) 有权
    通过施用物质P（sP）逆转近期发病1型糖尿病（T1D）的方法

    公开(公告)号：US09192647B2

    公开(公告)日：2015-11-24

    申请号：US14244990

    申请日：2014-04-04

    申请人： Hans-Michael Dosch

    发明人： Hans-Michael Dosch

    IPC分类号： A61K38/08 ,  A61P3/10 ,  A61K9/00 ,  C12Q1/68

    CPC分类号： C12Q1/6883 ,  A61K9/0019 ,  A61K38/046 ,  A61K38/08 ,  C12Q2600/106 ,  C12Q2600/156

    摘要： Described herein is a treatment comprising the following step: (a) injecting a therapeutically effective amount of a pharmaceutical composition into the celiac artery of an individual, wherein the pharmaceutical composition reverses recent onset Type 1 Diabetes (T1D). Also described is a method for identifying an individual who will be responsive to this treatment. In addition there is described a device containing the pharmaceutical composition for injecting the pharmaceutical composition into the celiac artery.

    摘要翻译： 本文描述的治疗包括以下步骤：（a）将治疗有效量的药物组合物注射到个体的腹腔动脉中，其中药物组合物逆转最近发病的1型糖尿病（T1D）。 还描述了一种用于识别对这种治疗有反应的个体的方法。 此外，还描述了含有用于将药物组合物注入腹腔动脉的药物组合物的装置。

    Prevention of primary Sjogren's Syndrome by ICA69 deficiency
    10.
    发明申请
    Prevention of primary Sjogren's Syndrome by ICA69 deficiency 审中-公开
    通过ICA69缺乏预防原发性干燥综合征

    公开(公告)号：US20060074022A1

    公开(公告)日：2006-04-06

    申请号：US11241450

    申请日：2005-09-30

    申请人： Hans-Michael Dosch ,  Shawn Winer

    发明人： Hans-Michael Dosch ,  Shawn Winer

    IPC分类号： A61K38/17 ,  G01N33/53 ,  A01K67/00

    CPC分类号： C12N15/8509 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0325 ,  A61K39/0008 ,  G01N33/564 ,  G01N2800/101

    摘要： This invention relates to identification of an autoantigen implicated in the development and progression of Sjögren's Syndrome (pSS); particularly to the disease modifying effect of creating a deficiency in the ICA69 autoantigen; and most particularly to development of diagnostic and therapeutic avenues, means for the differential diagnosis of pSS versus other autoimmune disease, e.g. Systemic lupus erythematosis (SLE), and procedures for immunotherapeutic treatment effective to alter the course and progression of pSS.

    摘要翻译： 本发明涉及鉴定涉及Sjögren综合征（pSS）发展和进展的自身抗原; 特别是在ICA69自身抗原中产生缺陷的疾病修复效果; 最特别地涉及诊断和治疗途径的发展，用于鉴别诊断pSS与其他自身免疫疾病的手段。 系统性红斑狼疮（SLE）和免疫治疗方法有效改变pSS的病程和进展。